Scharrer / Schramm 34th Hemophilia Symposium Hamburg 2003

HIV Infection and Epidemiology; Management of Bleedings in Hemophiliacs with Inhibitors;Orthopedic Problems and Therapy in Hemophiliacs;Therapy with Protein C;Pediatric Hemostaseology;Free Lectures
2005
ISBN: 978-3-540-27022-5
Verlag: Springer
Format: PDF
Kopierschutz: Wasserzeichen (»Systemvoraussetzungen)

E-Book, Englisch, 395 Seiten, eBook

This book contains the contributions to the 34th Hemophilia Symposium, Hamburg 2003. The main topics are HIV infection and epidemiology, management of bleedings in hemophiliacs with inhibitors, orthopedic problems and therapy in hemophiliacs, therapy with protein C and pediatric hemostaseology. The volume is rounded off by numerous free papers and posters on hemophilia, hemophiliacs with inhibitors, thrombophilia and molecular diagnostics.

Zielgruppe

Research

Autoren/Hrsg.

Scharrer, I.

Schramm, W.

Inhaltsverzeichnis

HIV Infection and Epidemiology.- HIV Infection and Causes of Death in Patients with Hemophilia in Germany (Year 2002/2003 Survey).- Hemophilia in Austria — The Annual Survey of the Austrian Hemophilia Centers.- Lithuanian Hemophilia Register: Update 2003.- Management of Bleedings in Hemophiliacs with Inhibitors.- Guidelines for Treatment of Patients with Hemophilia and Inhibitors.- Bolus Injection of Recombinant Factor VIIa (NovoSeven) can be More Effective than Continuous Infusion in Inhibitor Patients with Severe Hemophilia A.- The Role of Therapy Regimen and Age at First Exposure on Inhibitor Development in Patients with Severe Hemophilia A.- Presentation of the Inhibitor-Immunology-Study.- Current Clinical Investigations Involving FEIBA.- Orthopedic Problems and Therapy in Hemophiliacs.- Major Orthopedic Reconstructions in an Inhibitor Patient — A Case Report.- Total Hip Replacement in Patients with Severe Bleeding Disorders A 30 Years Single Center Experience.- MRI Staging of Hemophilic Joints in Comparison with the Radiological Score and the Clinical Dates of Children and Young Adults.- Orthopedic Knee Replacement in Hemophilic Patients.- Therapy with Protein C.- Treatment of Adults with Sepsis-Induced Coagulopathy and Purpura Fulminans with a Plasma-Derived Protein C Concentrate (Ceprotin).- Comparison of the Anticoagulant Action of Recombinant Human Activated Protein C in Cord with that in Adult Plasma.- The Relationship between Protein C Activity and the Endogenous Thrombin Potential in Controls and Septic Patients.- Pediatric Hemostaseology.- Antibodies Against Annexin V, Cardiolipin and ?2-Glycoprotein 1 or APC-Resistance in Patients with Recurrent Miscarriage or In-Vitro-Fertilization-Failures.- Diagnostics of Platelet Function Disorders by Lumi-Aggregometry — Results and Comparison of Methods.- Management of a Premature Infant below 1500 g with Hemophilia A.- Elevated Factor VIIIC: Ag in Children with Venous Thrombosis and Stroke — Preliminary Results of a Case-Control Study.- Functional Disorders and Treatment Modalities in Hemophilic Children.- Free Lectures.- HLA Profile in Acquired Hemophilia.- Characterization of Polyclonal Factor VIII-Inhibitory Antibodies.- Frequency and Inhibitor Risk of the Intron-1-Inversion Mutation in the German Hemophilia Population.- Effect of FVIII on Clotting Time and Thrombin Potential in Tissue Factor-Activated Hemophilia A Plasma.- Poster.- Bleeding Tendency in Factor XI Deficiency: Report on two Families and the Detection of a Novel Mutation within the Factor XI Gene.- Multiple Distal Pseudotumours in a Patient with Severe Hemophilia A and High Titer Inhibitors.- HIV Resistance to Antiretroviral Therapy in Romania.- Ileopsoas Hemophilic Pseudotumour with Externalized Bowel Fistulation.- Reduction of Proteoglycan Synthesis in Chondrocytes Depending on Concentration and Duration of Iron Overload.- Bleeding Tendency of Carriers of Hemophilia A — Dependent on the Age of the Carriers?.- Clinical Investigation of Orthopedic Outcome in Patients with Severe Hemophilia Under Prophylactic Treatment. Disadvantage of a late Prophylactic Treatment?.- Operative Treatment of Ankle Equinus Deformity in Hemophiliacs.- Spontaneous Empyema of Joints and Staphylococcal Sepsis in a Patient with Severe Hemophilia A.- The Role of VWF:Ag II in Patients with Acquired von Willebrand Disease.- Contamination of Coagulation Factor Concentrates with Human Parvovirus Genotype 2 DNA is Less Frequent than Contamination with Genotype 1 (B19) DNA.- The Hemophilia Assistant in Germany.- “Need” in Hemophilia A — a Qualitative Study.- Fit for Life — Fitness Levels of Young Hemophiliacs Today.- The Austrian “Haemofit-Program” - a two Years work-out Experience of People with Hemophilia (PwH).- Methods for Testing Pharmacodynamic Variables of Hemophilia and Inhibitor Therapy: Thrombin Generation Assay and Other Tests.- Immune Tolerance in an Inhibitor Patient with Severe Hemophilia A — Comparison of two Different Treatment Schedules Including Rituximab.- The Endogenous Thrombin Potential as a Monitoring Parameter in a Patient with an Acquired Hemophilia A.- Case report: 58-Year-Old Hemophilia A Patient with High-Titer Inhibitor Development and Introduction of a Multicenter PTP-Inhibitor Study.- First Data of a Prospective Study About Incidence of Inhibitors During and After Continuous Infusion of Different Factor Concentrates Given During and After Surgical Procedures in Hemophilia A or B and von Willebrand Disease.- Acquired Thrombophilia in Patients on Hemodialysis with Recurrent Vascular Access Thrombosis.- Is Travelling a Risk Factor for Venous Thrombosis in Individuals with Factor V Leiden in Heterozygous Form?.- Popliteal Artery Embolism in Abdominal Aortal Thrombus with Liver Abscesses Caused by Heterozygous Prothrombin Mutation with Protein S Deficiency and Factor VIII Elevation.- Effect of the new Direct Thrombin Inhibitor Melagatran in Cord and Adult Plasma: an in-vitro Examination.- Higher Concentrations of Heparin and Hirudin are Required to Inhibit Thrombin Generation in Tissue Factor-Activated Cord Compared to Adult Plasma.- Molecular Genetic Analysis in Patients with Inherited Thrombophilia and Antithrombin, Protein C or Protein S Deficiency.- Analysis of Thrombophilic Risk Factors in Patients Suffering from Ocular Thrombotic Complications.- Protein C Concentrate for the Treatment of Veno Occlusive Disease in a boy with Nephroblastoma.- Homozygous Factor X Gene Mutation Gly380Arg is Associated to Perinatal Intracranial Hemorrhage.- Mutation Analysis of the C1 Inhibitor Gene.- Novel and Recurrent Mutations in the Gamma-Glutamyl Carboxylase (GGCX) Gene.- First Case of Compound Heterozygous Mutations in the Kininogen Gene Causing Severe High Molecular Weight Kininogen Deficiency.- Sequence of the rat Factor VIII cDNA.- Mutation Profiling in Congenital FXIIIA Deficiency: Detection of 6 Novel Mutations.- Functional Analysis of the Factor VIII B Domain.- Expressing Recombinant Coagulation Factors in Yeast and Insect Cells.- Long Term Optimisation of F8 Gene Mutation Screening by DHPLC.- Expression Studies of Recombinant FVIII Proteins Exhibiting Mutations in the B-Domain.- Genetic Variability of the Factor VIII Gene in the Normal Population.- Three Novel Microdeletions and the First Insertion / Deletion in Patients with Factor X Deficiency.- SNP Map of the Protein C Gene.- Characterization of Factor VIII-Von Willebrand Factor (FVIII-VWF)-Complex Concentrates Under Shear Stress.- Procedural Rules of a National Hemophilia Register in Germany.- Quality Management of Clotting Factor Replacement Therapy in Medical Institutions — Advantage or Obligation.- Proteus Syndrome: Successful Therapy of Severe Migraine Symptoms with low Molecular Weight Heparin.- Administration of Recombinant Factor FVIIa (NovoSeven, NovoNordisk) in a Patient with Glanzmann Thrombasthenia.- Combined Heterozygous Factor XIII-Deficiency in a Family Case Report.- Resistance to Coumarin in a 55-year-old Patient with Chronic Arrhythmia.- Investigation of the Tendency to Bleeding in Patients with low Activity of Plasminogen Activator Inhibitor-1 (PAI-1).- The Importance of Pre-Analytic Conditions on the Determination of VWF Parameters.- Recombinant FVIIa in Chemotherapy Related Thrombocytopenic Bleedings.